Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia

ClinicalTrials.gov ID: NCT00280423

Public ClinicalTrials.gov record NCT00280423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 28 Day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial.

Study identification

NCT ID
NCT00280423
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
342 participants

Conditions and interventions

Interventions

  • GW679769 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2005
Primary completion
Jan 31, 2007
Completion
Jan 31, 2007
Last update posted
Apr 14, 2015

2006 – 2007

United States locations

U.S. sites
61
U.S. states
26
U.S. cities
53
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35213
GSK Investigational Site Phoenix Arizona 85050
GSK Investigational Site Tucson Arizona 85712
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Burbank California 91506
GSK Investigational Site Huntington Beach California 92648
GSK Investigational Site Irvine California 92618
GSK Investigational Site Los Angeles California 90048
GSK Investigational Site National City California 91950
GSK Investigational Site San Diego California 92121
GSK Investigational Site San Diego California 92123
GSK Investigational Site San Diego California 92161
GSK Investigational Site San Francisco California 94105
GSK Investigational Site Santa Rosa California 95405
GSK Investigational Site Norwalk Connecticut 06850
GSK Investigational Site DeLand Florida 32720
GSK Investigational Site Delray Beach Florida 33484
GSK Investigational Site Hallandale Florida 33009
GSK Investigational Site Largo Florida 33773
GSK Investigational Site Miami Florida 33143
GSK Investigational Site Miami Florida 33173
GSK Investigational Site Miami Florida 33176
GSK Investigational Site Pembroke Pines Florida 33026
GSK Investigational Site Atlanta Georgia 30328
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Gainesville Georgia 30501
GSK Investigational Site Hinesville Georgia 31313
GSK Investigational Site Macon Georgia 31201
GSK Investigational Site Stockbridge Georgia 30281
GSK Investigational Site Chicago Illinois 60611
GSK Investigational Site Chicago Illinois 60612
GSK Investigational Site Chicago Illinois 60634
GSK Investigational Site Overland Park Kansas 66211
GSK Investigational Site Crestview Hills Kentucky 41017
GSK Investigational Site Rockville Maryland 20852
GSK Investigational Site Newton Massachusetts 02459
GSK Investigational Site Troy Michigan 48085
GSK Investigational Site Hattiesburg Mississippi 39404
GSK Investigational Site Las Vegas Nevada 89104
GSK Investigational Site Clementon New Jersey 08021
GSK Investigational Site West Seneca New York 14224
GSK Investigational Site Durham North Carolina 27705
GSK Investigational Site Salisbury North Carolina 28144
GSK Investigational Site Winston-Salem North Carolina 27157
GSK Investigational Site Beachwood Ohio 44122
GSK Investigational Site Cincinnati Ohio 45227
GSK Investigational Site Cincinnati Ohio 45246
GSK Investigational Site Cleveland Ohio 44130
GSK Investigational Site Gallipolis Ohio 45631
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Gresham Oregon 97020
GSK Investigational Site Clarks Summit Pennsylvania 18411
GSK Investigational Site Duncansville Pennsylvania 16635
GSK Investigational Site Warwick Rhode Island 02886
GSK Investigational Site Columbia South Carolina 29201
GSK Investigational Site Austin Texas 78756
GSK Investigational Site Bellaire Texas 77401
GSK Investigational Site Dallas Texas 75251
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Plano Texas 75093
GSK Investigational Site Salt Lake City Utah 84107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00280423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2015 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00280423 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →